| Website | cardioxyl.com |
| Category | BioTech |
| Phone | (919) 869-8585 |
| Employees | |
| Founded | 2005 |
| TOTAL | $29.5M |
| VENTURE FUNDING TOTAL | $29.5M |
| Series A, 12/06 The Aurora Funds New Enterprise Associates | $14.5M |
| Series C, 10/10 The Aurora Funds New Enterprise Associates | $15M |
Cardioxyl Pharmaceuticals is a privately held, clinical stage biopharmaceutical company developing therapies for the treatment of cardiovascular disease, focusing on the discovery, development and commercialization of novel technologies for disease areas where current therapies don’t exist, are ineffective or are inadequate.
Cardioxyl has developed industry-leading expertise in the chemistry, biology and clinical applications of nitroxyl technology. The company’s core nitroxyl platform has generated several pre-clinical and clinical candidates including the company’s lead compound, CXL-1020, currently in clinical development for Acute Decompensated Heart Failure, the most common cause of hospitalization for patients older than 65 years of age.
